Geoffrey H. Rosen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Geoffrey H. Rosen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Katie S. Murray
Department of Urology
9 shared publications - Mojgan Golzy
University of Missouri, USA
5 shared publications Katie S. Murray
Department of Urology, NYU-Langone Health, New York, New York
3 shared publications- Paige Ashley Hargis
Division of Urology
3 shared publications Alp Kahveci
School of Medicine
2 shared publications- Andrew Moss
Department of Anesthesia
2 shared publications
Latest Publications
- Open Access
Relationship Among Body Mass Index, Survival, Cancer Treatment and Health-Related Quality of Life Among Older Patients with Bladder Cancer
Background: The relationship between body composition and bladder cancer outcomes is complex. While a higher body mass index (BMI) has been associated with an increased risk of bladder cancer development, its impact on survival outcomes is less clear. This study aimed to explore the association between BMI, survival, health-related quality of life, and the performance of ADLs in a cohort of older patients with bladder cancer. Methods: Data were obtained from the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey, including patients diagnosed with bladder cancer who had recorded BMI values. Analysis of variance was used to assess the association between BMI categories and patient demographics as well as cancer/treatment characteristics. Generalized linear models examined the impact of BMI on health-related quality of life, as measured by the physical and mental component summary scores when controlling for confounding variables. Kaplan–Meier survival curves across BMI categories were compared using log-rank tests. Results: The final cohort consisted of 8013 patients (age ≥ 65) with a mean age of 77.7 ± 7.1 years, the majority of whom were White (85.6%) and male (74.8%). We observed no significant association between BMI and cancer/treatment characteristics. The severely obese subgroup had the highest rate of disability in performing ADLs (18.3%) followed by the underweight subgroup (10.3%). Overweight patients exhibited the highest physical and mental component summary scores, indicating better health-related quality of life. BMI was a significant predictor of overall survival, with overweight, obese, and severely obese patients demonstrating improved survival compared to those with healthy or underweight BMI. These findings remained statistically significant in multivariable analysis. Conclusions: Our findings suggest a dual role of BMI in older patients with bladder cancer: higher BMI provides a survival advantage and, to an extent, a QoL advantage. At the same time, severe obesity did lead to the lowest QoL despite improved survival outcomes. These results underscore the complex interplay between BMI, survival, and QoL in this bladder cancer population.
Open AccessRelationship Among Body Mass Index, Survival, Cancer Treatment and Health-Related Quality of Life Among Older Patients with Bladder Cancer
Background: The relationship between body composition and bladder cancer outcomes is complex. While a higher body mass index (BMI) has been associated with an increased risk of bladder cancer development, its impact on survival outcomes is less clear. This study aimed to explore the association between BMI, survival, health-related quality of life, and the performance of ADLs in a cohort of older patients with bladder cancer. Methods: Data were obtained from the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey, including patients diagnosed with bladder cancer who had recorded BMI values. Analysis of variance was used to assess the association between BMI categories and patient demographics as well as cancer/treatment characteristics. Generalized linear models examined the impact of BMI on health-related quality of life, as measured by the physical and mental component summary scores when controlling for confounding variables. Kaplan–Meier survival curves across BMI categories were compared using log-rank tests. Results: The final cohort consisted of 8013 patients (age ≥ 65) with a mean age of 77.7 ± 7.1 years, the majority of whom were White (85.6%) and male (74.8%). We observed no significant association between BMI and cancer/treatment characteristics. The severely obese subgroup had the highest rate of disability in performing ADLs (18.3%) followed by the underweight subgroup (10.3%). Overweight patients exhibited the highest physical and mental component summary scores, indicating better health-related quality of life. BMI was a significant predictor of overall survival, with overweight, obese, and severely obese patients demonstrating improved survival compared to those with healthy or underweight BMI. These findings remained statistically significant in multivariable analysis. Conclusions: Our findings suggest a dual role of BMI in older patients with bladder cancer: higher BMI provides a survival advantage and, to an extent, a QoL advantage. At the same time, severe obesity did lead to the lowest QoL despite improved survival outcomes. These results underscore the complex interplay between BMI, survival, and QoL in this bladder cancer population.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (10)
Reply to Editorial Comment: Transition in Quality Of Life Among Older Patients With Bladder Cancer and Its Association With Treatment: A Clustering Approach
- 1 October 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (10)
Open AccessReply to Editorial Comment: Transition in Quality Of Life Among Older Patients With Bladder Cancer and Its Association With Treatment: A Clustering Approach
- Open Access
- 1 September 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Transition in Quality Of Life Among Older Patients With Bladder Cancer and Its Association With Treatment: A Clustering Approach
Purpose: To classify older patients with bladder cancer (BC) based on quality-of-life (QoL) measures and explore the clusters transitions over a 2-year period and patient characteristics, BC stages, and treatment. Patients with BC report a significant decline in functional status and QoL. The association of this transition and patient characteristics and treatment over time is not known. We aim to explore this association. Methods: Data were obtained from patients with BC in the SEER-MHOS database (1998-2021). Unsupervised cluster analysis was employed to identify homogeneous clusters of patients with similar functionality based on age, physical and mental component score, and ability to perform activities of daily living. Univariate and multivariable analyses were performed to assess the association of patient characteristics and treatment on cluster transitions over a 2-year interval. Results: The final cohort consisted of 2934 (age 65 or older) older patients with BC. We identified 3 distinct clusters: 67.9% in Cluster 1; 25.4% in Cluster 2; and 6.7% in Cluster 3. After 2 years, 11.7% patients showed improvement and 14% experienced a decline. Cancer/treatment characteristics were not associated with cluster transition. Younger age and being married were identified as factors associated with improvement. Older age, non–homeownership, and last-year fall were associated with transition to less healthy cluster. Conclusions: Over a 2-year interval after BC diagnosis, a quarter of patients will have substantial changes in QoL. No significant association was observed between cluster transition and BC characteristics. Age as well as marital, fall, and homeowner status do impact this transition.
- 1 September 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Open AccessTransition in Quality Of Life Among Older Patients With Bladder Cancer and Its Association With Treatment: A Clustering Approach
Purpose: To classify older patients with bladder cancer (BC) based on quality-of-life (QoL) measures and explore the clusters transitions over a 2-year period and patient characteristics, BC stages, and treatment. Patients with BC report a significant decline in functional status and QoL. The association of this transition and patient characteristics and treatment over time is not known. We aim to explore this association. Methods: Data were obtained from patients with BC in the SEER-MHOS database (1998-2021). Unsupervised cluster analysis was employed to identify homogeneous clusters of patients with similar functionality based on age, physical and mental component score, and ability to perform activities of daily living. Univariate and multivariable analyses were performed to assess the association of patient characteristics and treatment on cluster transitions over a 2-year interval. Results: The final cohort consisted of 2934 (age 65 or older) older patients with BC. We identified 3 distinct clusters: 67.9% in Cluster 1; 25.4% in Cluster 2; and 6.7% in Cluster 3. After 2 years, 11.7% patients showed improvement and 14% experienced a decline. Cancer/treatment characteristics were not associated with cluster transition. Younger age and being married were identified as factors associated with improvement. Older age, non–homeownership, and last-year fall were associated with transition to less healthy cluster. Conclusions: Over a 2-year interval after BC diagnosis, a quarter of patients will have substantial changes in QoL. No significant association was observed between cluster transition and BC characteristics. Age as well as marital, fall, and homeowner status do impact this transition.
- 24 April 2024
- Published by Elsevier in European Urology
- Vol. 86 (1) , e14
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68
- 24 April 2024
- Published by Elsevier in European Urology
- Vol. 86 (1) , e14
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68
- 1 September 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (3) , 528
Reply by Authors
- 1 September 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (3) , 528
Reply by Authors
- 1 September 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (3) , 517-528
Randomized Controlled Trial of Single-dose Perioperative Pregabalin in Ureteroscopy
Ureteroscopy is a commonly performed procedure, with post operative pain that can lead to re-visits and opioid prescribing. Perioperative gabapentinoids have shown promise in decreasing pain and opioid use. We hypothesized that single dose perioperative pregabalin would be safe and efficacious for decreasing pain after ureteroscopy. This was an IRB approved and registered blinded, placebo-controlled trial conducted at a single institution. Patients undergoing ureteroscopy without histories that would limit use of opioids, gabapentinoids, and non-steroidal medications were enrolled. Either 300mg pregabalin or placebo was administered 1 hour before ureteroscopy. Pain was assessed using a visual analogue before administration and 1 hour after surgery. Clinical factors, pain scores, a proxy for cognition, patient satisfaction, and opioid prescribing were assessed in the first 30 post operative days. 118 patients were enrolled over a 2-year period. Patients who received pregabalin were younger than those who received placebo (median of 44 years vs 57). Post operative pain scores were higher in those who received pregabalin (3.7 vs 2.0, P = .004), a finding that remained statistically significant when accounting for patient age and preoperative pain scores. There was no difference in the measure of cognition or in reports of adverse events. In this trial evaluating the efficacy of a single dose perioperative pregabalin in ureteroscopy, pregabalin did not decrease postoperative pain when compared to placebo. Urologists should not routinely use this adjunctive medication in ureteroscopy, as it is unlikely to provide benefit.
- 1 September 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (3) , 517-528
Randomized Controlled Trial of Single-dose Perioperative Pregabalin in Ureteroscopy
Ureteroscopy is a commonly performed procedure, with post operative pain that can lead to re-visits and opioid prescribing. Perioperative gabapentinoids have shown promise in decreasing pain and opioid use. We hypothesized that single dose perioperative pregabalin would be safe and efficacious for decreasing pain after ureteroscopy. This was an IRB approved and registered blinded, placebo-controlled trial conducted at a single institution. Patients undergoing ureteroscopy without histories that would limit use of opioids, gabapentinoids, and non-steroidal medications were enrolled. Either 300mg pregabalin or placebo was administered 1 hour before ureteroscopy. Pain was assessed using a visual analogue before administration and 1 hour after surgery. Clinical factors, pain scores, a proxy for cognition, patient satisfaction, and opioid prescribing were assessed in the first 30 post operative days. 118 patients were enrolled over a 2-year period. Patients who received pregabalin were younger than those who received placebo (median of 44 years vs 57). Post operative pain scores were higher in those who received pregabalin (3.7 vs 2.0, P = .004), a finding that remained statistically significant when accounting for patient age and preoperative pain scores. There was no difference in the measure of cognition or in reports of adverse events. In this trial evaluating the efficacy of a single dose perioperative pregabalin in ureteroscopy, pregabalin did not decrease postoperative pain when compared to placebo. Urologists should not routinely use this adjunctive medication in ureteroscopy, as it is unlikely to provide benefit.
- 1 July 2022
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 9 (4) , 282-283
Reply by Authors
- 1 July 2022
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 9 (4) , 282-283
Reply by Authors
- Open Access
- 1 July 2022
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 9 (4) , 279-283
Changes in Use of Oral Androgen Pathway Directed Medications during the COVID-19 Era
- 1 July 2022
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 9 (4) , 279-283
Open AccessChanges in Use of Oral Androgen Pathway Directed Medications during the COVID-19 Era